- Home
- PRHI vs IMRN Comparison
PRHI vs IMRN Comparison
Compare PRHI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRHI
- IMRN
- Stock Information
- Founded
- PRHI 2009
- IMRN 1994
- Country
- PRHI United States
- IMRN Australia
- Employees
- PRHI N/A
- IMRN N/A
- Industry
- PRHI Property-Casualty Insurers
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PRHI Finance
- IMRN Health Care
- Exchange
- PRHI Nasdaq
- IMRN Nasdaq
- Market Cap
- PRHI 13.7M
- IMRN 14.4M
- IPO Year
- PRHI N/A
- IMRN N/A
- Fundamental
- Price
- PRHI $1.45
- IMRN $2.20
- Analyst Decision
- PRHI
- IMRN
- Analyst Count
- PRHI 0
- IMRN 0
- Target Price
- PRHI N/A
- IMRN N/A
- AVG Volume (30 Days)
- PRHI 2.1M
- IMRN 95.9K
- Earning Date
- PRHI 11-12-2025
- IMRN 08-29-2025
- Dividend Yield
- PRHI N/A
- IMRN N/A
- EPS Growth
- PRHI N/A
- IMRN N/A
- EPS
- PRHI 2.45
- IMRN N/A
- Revenue
- PRHI $52,654,000.00
- IMRN $4,777,422.00
- Revenue This Year
- PRHI $25.91
- IMRN N/A
- Revenue Next Year
- PRHI N/A
- IMRN N/A
- P/E Ratio
- PRHI $0.60
- IMRN N/A
- Revenue Growth
- PRHI N/A
- IMRN 48.63
- 52 Week Low
- PRHI $0.42
- IMRN $1.50
- 52 Week High
- PRHI $2.83
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- PRHI N/A
- IMRN 58.40
- Support Level
- PRHI N/A
- IMRN $2.09
- Resistance Level
- PRHI N/A
- IMRN $2.24
- Average True Range (ATR)
- PRHI 0.00
- IMRN 0.14
- MACD
- PRHI 0.00
- IMRN -0.01
- Stochastic Oscillator
- PRHI 0.00
- IMRN 55.00
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.